Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
about
Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritisNebivolol: a novel beta-blocker with nitric oxide-induced vasodilatationNew Insight into Effects of β-Blockers on Arterial FunctionsVascular endothelial dysfunction and pharmacological treatmentExploiting the Pleiotropic Antioxidant Effects of Established Drugs in Cardiovascular DiseaseA Review of Nebivolol Pharmacology and Clinical EvidenceClinical significance of erectile dysfunction developing after acute coronary event: exception to the rule or confirmation of the artery size hypothesis?Nebivolol: third-generation beta-blockadeThe influence of new beta-adrenolytics nebivolol and carvedilol on intraocular pressure and iris blood flow in rabbitsValsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study.Is reversal of endothelial dysfunction still an attractive target in modern cardiology?Vascular endothelial function and hypertension: insights and directionsNebivolol attenuates redox-sensitive glomerular and tubular mediated proteinuria in obese rats.Clinical utility of fixed-dose combinations in hypertension: evidence for the potential of nebivolol/valsartan.The favorable kinetics and balance of nebivolol-stimulated nitric oxide and peroxynitrite release in human endothelial cells.Nebivolol: a review.Nebivolol: impact on cardiac and endothelial function and clinical utility.The influence of CYP2D6 phenotype on the clinical response of nebivolol in patients with essential hypertensionEffect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertensionThe Beta-1-Receptor Blocker Nebivolol Elicits Dilation of Cerebral Arteries by Reducing Smooth Muscle [Ca2+]iEndothelial function and its assessment.The effect of AVE 0991, nebivolol and doxycycline on inflammatory mediators in an apoE-knockout mouse model of atherosclerosis.Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive ratsA review of the safety and efficacy of nebivolol in the mildly hypertensive patient.Nitric Oxide Contributes to Vasomotor Tone in Hypertensive African Americans Treated With Nebivolol and Metoprolol.Nebivolol for heart failure in the elderly.Comprehensive Assessment of Coronary Plaque Progression With Advanced Intravascular Imaging, Physiological Measures, and Wall Shear Stress: A Pilot Double-Blinded Randomized Controlled Clinical Trial of Nebivolol Versus Atenolol in Nonobstructive CoChronic Nebivolol Treatment Suppresses Endothelin-1-Mediated Vasoconstrictor Tone in Adults With Elevated Blood Pressure.Hypertension treatment in the Asia-Pacific: the role of and treatment strategies with nebivololNebivolol: pharmacologic profile of an ultraselective, vasodilatory beta1-blocker.Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function.The effects of nebivolol on fibrinolytic parameters in mild and moderate hypertensive patientsBeta-blockers in the management of hypertension: focus on nebivolol.Pharmacological approaches to improve endothelial repair mechanisms.Nitric oxide mechanisms of nebivolol.Arterial stiffness, hypertension, and rational use of nebivolol.Assessment of endothelial dysfunction.Novel therapeutic strategies targeting vascular endothelium in essential hypertension.β-blockade: benefits beyond blood pressure reduction?Adrenoreceptors and nitric oxide in the cardiovascular system.
P2860
Q21195404-0CF5D083-6B76-4FC5-B2C6-EBA1A2EE52AEQ24681317-E6C3215C-AF56-4549-8429-306E3C8F131FQ26747936-7C6BF4C6-9303-4951-B970-C1BA50A17DA0Q26774561-20637830-D1CB-4DA8-A9C5-648E3B9EE584Q26801173-3B1AB10C-4EC4-40FE-8FD4-0CC441B3E670Q26801287-88230B59-AE7A-41D0-A0C0-FB3E6B34E8A6Q26829068-AE1CB287-A730-4B72-9C84-350352D5D359Q28238369-82A83FDF-41F4-4099-8280-C5A9CB58B0D9Q33671857-8C28CFE0-3421-46DF-BEAE-0C668C063C3BQ34167806-8D8145D0-5E62-493F-B4D9-AEF5DD9DB54EQ34179077-67799A83-B13B-4A92-A5FE-118D2856583AQ34316160-FE2003B3-43F7-45B7-938C-71C9C50480ACQ34566577-650EF21B-2AC8-41EC-9D76-53CF8582085EQ34609451-F549EAEB-786F-44B5-98FE-D538C6C4C1D5Q35001265-131D2257-9066-43FF-82DB-C7B32CE36BBDQ35753422-193FB05D-9D7C-4E92-BAE2-951539AB8BD0Q35846698-E1B259F2-4F9F-4DAA-A672-506CD8CB78D5Q36025103-6BCF93D4-2FAB-4EE2-874F-94F900F082DBQ36072467-BF102A2E-C96E-4042-811D-D1719255F8EEQ36157478-D460FC2D-1781-474D-AF06-92E26CDF9943Q36300017-E2A264E8-B0DD-47F4-AE8D-CE3F24B9603EQ36576745-A1F98947-36E9-4CD8-B85D-6E101EEC73D0Q36596813-3DDCE4EA-16D9-4CDA-A5A5-DA7DE62294ACQ36596852-64260A97-3E58-4D14-8DF6-054756C65598Q36599312-44D6A1D1-1963-42BC-9CD2-D870D5661E72Q36815960-3B7AE0E4-76F1-4407-8DD3-5C302D4517A7Q36877809-9A50E7D7-AFBF-498D-B181-60D687E20684Q36912685-4E056997-4781-4A6D-A2BF-2355C9F622ABQ36982759-63F59BE5-BA58-493F-B0A5-E4209F33A45BQ37033656-1F518558-5031-4AB0-B3A8-50F32271CB52Q37102837-BB203FD0-2631-42EB-B3D8-8E1A0DF57E3BQ37119116-E908BB85-2257-4451-A68E-CC07F534633FQ37134471-B8CCADBE-0961-4275-9AC4-20BB0446F829Q37269376-8F6E7879-F104-4E2D-8265-8B853DA86E17Q37483065-385E7F47-7B33-4AD3-A574-72B4FBBD3AD8Q37498585-0628AAE7-6ECB-4E9A-833A-98D1A5721FA6Q37732250-6DD1C219-9FDC-4053-B882-9EFE7C2957D2Q37798006-93F01CDA-6633-4D8E-B1F5-4433CE6AE04BQ37978685-BA18E921-2915-462B-AFB7-1F31B9B76E68Q38162217-6E6529B4-6DA0-4664-B34B-6360DEAD721E
P2860
Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Nebivolol reverses endothelial ...... double-blind, crossover study.
@en
type
label
Nebivolol reverses endothelial ...... double-blind, crossover study.
@en
prefLabel
Nebivolol reverses endothelial ...... double-blind, crossover study.
@en
P356
P1433
P1476
Nebivolol reverses endothelial ...... double-blind, crossover study
@en
P304
P356
10.1161/HC3001.094207
P407
P577
2001-07-01T00:00:00Z